Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs

Multiple Sclerosis Journal

Volumn 18, Issue 4, 2012, Pages 460-467

  Lu, E ^a   Dahlgren, L ^a   Sadovnick, A D ^a   Sayao, A ^a   Synnes, A ^a   Tremlett, H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

birth; disease modifying therapies; glatiramer acetate; interferon beta; multiple sclerosis; pregnancy; relapsing remitting

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; DISEASE MODIFYING DRUG; DRUG; GLATIRAMER; INTERFERON BETA SERINE; UNCLASSIFIED DRUG;

ADULT; APGAR SCORE; ARTICLE; BIRTH WEIGHT; CONGENITAL MALFORMATION; CONTROLLED STUDY; DATA BASE; DELIVERY; DRUG EFFECT; DRUG SAFETY; FEMALE; FETUS OUTCOME; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANCY OUTCOME; RISK ASSESSMENT;

EID: 84859411133     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511422244     Document Type: Article

References (38)

1. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. 2009 ; 15: 1037-1042
2. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001 ; 10: 407-410
3. Coyle PK, Christie S, Fodor P, Fuchs K, Giesser B, Gutierrez A, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler. 2004 ; 10: 582-588
4. Neura.net. Pregnancy in MS: Treatment during pregnancy [online]. Available at: www.neura.net/channels/1.asp?id=512&prev-place=&cps= 0&cpp=2 (accessed 23 August 2010).
5. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect. 1998 ; 30: 24 46-29
6. Biogen Idec. Avonex (interferon beta-1a) [online]. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2007/103628s5115lbl.pdf (accessed 14 December 2010).
7. Merck Serono. Rebif (interferon beta-1a) [online]. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2005/103780s5062lbl.pdf (accessed 14 December 2010).
8. Bayer HealthCare. Betaseron (interferon beta-1b) [online]. Available at: berlex.bayerhealthcare.com/html/products/pi/Betaseron-PI.pdf (accessed 14 December 2010).
9. Teva Pharmaceuticals. Copaxone (glatiramer acetate) [online]. Available at: www.copaxone.com/pdf/prescribinginformation.pdf (accessed 14 December 2010).
10. Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, et al. Pregnancy and fetal outcomes after interferon-[beta] exposure in multiple sclerosis. Neurology. 2010 ; 75: 1794-1802
11. Patti F, Cavallaro T, Lo Fermo S, Nicoletti A, Cimino V, Vecchio R, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?. J Neurol. 2008 ; 255: 1250-1253
12. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 2010 ; 257: 2020-2023
13. British Columbia Perinatal Health Program. British Columbia perinatal database registry annual report 2007 [online]. Available at: www.perinatalservicesbc.ca/sites/bcrcp/files/AnnualReport/BCPHP-2007AR.pdf (accessed 23 August 2010).
14. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology. 1992 ; 42: 991-994
15. Sweeney VP, Sadovnick AD, Brandejs V. Prevalence of multiple sclerosis in British Columbia. Can J Neurol Sci. 1986 ; 13: 47-51
16. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231
17. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al Ann Neurol. 2001: 121-127.
18. Blondel B, Kogan MD, Alexander GR, Dattani N, Kramer MS, Macfarlane A, et al. The impact of the increasing number of multiple births on the rates of preterm birth and low birthweight: an international study. Am J Public Health. 2002 ; 92: 1323-1330
19. Baskett TF, Nagele F. Naegele's rule: a reappraisal. BJOG. 2000 ; 107: 1433-1435
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
21. Holt VL, Mueller BA. Attempt and success rates for vaginal birth after Caesarean section in relation to complications of the previous pregnancy. Paediatr Perinat Epidemiol. 1997 ; 11: 63-72
22. Jepson HA, Talashek ML, Tichy AM. The Apgar score: evolution, limitations, and scoring guidelines. Birth. 1991 ; 18: 83-92
23. Marden PM, Smith DW, McDonald MJ. Congenital anomalies in the newborn infant, including minor variations. A study of 4,412 babies by surface examination for anomalies and buccal smear for sex chromatin. J Pediatr. 1964 ; 64: 357-371
24. Jalkanen A, Alanen A, Airas L. Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler. 2010 ; 16: 950-955
25. British Columbia Ministry of Health Services. Disease modifying drug coverage for multiple sclerosis [online]. Available at: www.health.gov.bc.ca/ exforms/pharmacare/5351fil.pdf (accessed 12 March 2011).
26. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology. 2007 ; 68: S8-11
27. Cepok S, Schreiber H, Hoffmann S, Zhou D, Neuhaus O, von Geldern G, et al. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol. 2009 ; 66: 1216-1223
28. Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 2005 ; 65: 1961-1963
29. van der Kop ML, Pearce MS, Dahlgren L, Synnes A, Sadovnick AD, Sayao A, et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol. 2011 ; 70: 41-50
30. Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med. 2001 ; 344: 467-471
31. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology. 2005 ; 65: 807-811
32. Fragoso YD, Finkelsztejn A, Comini-Frota ER, Da Gama PD, Grzesiuk AK, Khouri JMN, et al. Pregnancy and multiple sclerosis: the initial results from a Brazilian database. Arq Neuropsiquiatr. 2009 ; 67: 657-660
33. Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, Grzesiuk AK, Gallina AS, Lopes J, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs. 2010 ; 24: 969-976
34. Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, Stam-Moraga M, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology. 2005 ; 65: 802-806
35. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011 ; 17: 423-430
36. Fernandez Liguori N, Klajn D, Acion L, Caceres F, Calle A, Carra A, et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). Mult Scler. 2009 ; 15: 555-562
37. Dwosh E, Guimond C, Sadovnick AD. Reproductive counselling for MS: a rationale. Int MS J. 2003 ; 10: 52-59
38. Dwosh E, Guimond C, Sadovnick AD. Reproductive counselling in MS: a guide for healthcare professionals. Int MS J. 2003 ; 10: 67